{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:33:26Z","timestamp":1790775206896,"version":"4.1.0"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000027","name":"NIAAA","doi-asserted-by":"crossref","award":["U01 AA026980-06"],"award-info":[{"award-number":["U01 AA026980-06"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hepatology Rep"],"DOI":"10.1007\/s11901-025-00712-8","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T01:26:33Z","timestamp":1763515593000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Met-ALD and ALD- Does Differentiating These Impact Management and Clinical Outcomes?"],"prefix":"10.1007","volume":"24","author":[{"given":"Fatima","family":"Elmustafa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahima","family":"Tyagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harpreet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4919-9519","authenticated-orcid":false,"given":"Hanna","family":"Blaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chencheng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2315-2384","authenticated-orcid":false,"given":"Sajid","family":"Jalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwani K.","family":"Singal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"issue":"5","key":"712_CR1","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, et al. Aasld practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797\u2013835.","journal-title":"Hepatology"},{"key":"712_CR2","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000828","author":"N Dunn","year":"2025","unstructured":"Dunn N, et al. Metabolic dysfunction and alcohol-associated liver disease: a narrative review. Clin Transl Gastroenterol. 2025. https:\/\/doi.org\/10.14309\/ctg.0000000000000828.","journal-title":"Clin Transl Gastroenterol"},{"issue":"10190","key":"712_CR3","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1016\/S0140-6736(18)32744-2","volume":"393","author":"J Manthey","year":"2019","unstructured":"Manthey J, et al. Global alcohol exposure between 1990 and 2017 and forecasts until 2030: a modelling study. Lancet. 2019;393(10190):2493\u2013502.","journal-title":"Lancet"},{"issue":"1","key":"712_CR4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jceh.2022.09.001","volume":"13","author":"A Aslam","year":"2023","unstructured":"Aslam A, Kwo PY. Epidemiology and disease burden of alcohol associated liver disease. J Clin Exp Hepatol. 2023;13(1):88\u2013102.","journal-title":"J Clin Exp Hepatol"},{"issue":"4","key":"712_CR5","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335\u201347.","journal-title":"Hepatology"},{"issue":"2","key":"712_CR6","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jhep.2023.03.040","volume":"79","author":"MH Le","year":"2023","unstructured":"Le MH, et al. Global incidence of non-alcoholic fatty liver disease: a systematic review and meta-analysis of 63 studies and 1,201,807 persons. J Hepatol. 2023;79(2):287\u201395.","journal-title":"J Hepatol"},{"issue":"9","key":"712_CR7","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851\u201361.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"712_CR8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jama.2021.7683","volume":"326","author":"AK Singal","year":"2021","unstructured":"Singal AK, Mathurin P. Diagnosis and treatment of alcohol-associated liver disease: a review. JAMA. 2021;326(2):165\u201376.","journal-title":"JAMA"},{"issue":"7","key":"712_CR9","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.dld.2024.01.195","volume":"56","author":"K Scholten","year":"2024","unstructured":"Scholten K, et al. You can\u2019t handle the truth! Comparing serum phosphatidylethanol to self-reported alcohol intake in chronic liver disease patients. Dig Liver Dis. 2024;56(7):1215\u20139.","journal-title":"Dig Liver Dis"},{"issue":"6","key":"712_CR10","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S2468-1253(23)00453-3","volume":"9","author":"PN Brennan","year":"2024","unstructured":"Brennan PN, et al. Progress is impossible without change: understanding the evolving nomenclature of steatotic liver disease and its effect on hepatology practice. Lancet Gastroenterol Hepatol. 2024;9(6):577\u201382.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"712_CR11","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s40429-021-00402-7","volume":"8","author":"JC Harris","year":"2021","unstructured":"Harris JC, Leggio L, Farokhnia M. Blood biomarkers of alcohol use: a scoping review. Curr Addict Rep. 2021;8(4):500\u20138.","journal-title":"Curr Addict Rep"},{"issue":"Suppl 2","key":"712_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1046\/j.1359-6357.2003.00588.x","volume":"98","author":"FM Wurst","year":"2003","unstructured":"Wurst FM, Skipper GE, Weinmann W. Ethyl glucuronide\u2013the direct ethanol metabolite on the threshold from science to routine use. Addiction. 2003;98(Suppl 2):51\u201361.","journal-title":"Addiction"},{"issue":"1","key":"712_CR13","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000003","volume":"7","author":"J Blomdahl","year":"2023","unstructured":"Blomdahl J, et al. Moderate alcohol consumption is associated with significant fibrosis progression in NAFLD. Hepatol Commun. 2023;7(1):e0003.","journal-title":"Hepatol Commun"},{"issue":"4","key":"712_CR14","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.jhep.2024.11.028","volume":"82","author":"JP Arab","year":"2025","unstructured":"Arab JP, et al. Metabolic dysfunction and alcohol-related liver disease (MetALD): position statement by an expert panel on alcohol-related liver disease. J Hepatol. 2025;82(4):744\u201356.","journal-title":"J Hepatol"},{"key":"712_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.04.019","author":"J Vaz","year":"2025","unstructured":"Vaz J, et al. Phosphatidylethanol levels distinguish steatotic liver disease subgroups and are associated with risk of major liver outcomes. J Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.jhep.2025.04.019.","journal-title":"J Hepatol"},{"issue":"6","key":"712_CR16","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.cgh.2023.11.003","volume":"22","author":"M Kalligeros","year":"2024","unstructured":"Kalligeros M, et al. Prevalence of steatotic liver disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017\u20132020. Clin Gastroenterol Hepatol. 2024;22(6):1330-1332 e4.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"712_CR17","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1111\/apt.17958","volume":"59","author":"CV Schneider","year":"2024","unstructured":"Schneider CV, et al. Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population. Aliment Pharmacol Ther. 2024;59(10):1271\u201381.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"712_CR18","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1097\/HEP.0000000000000604","volume":"79","author":"BP Lee","year":"2024","unstructured":"Lee BP, Dodge JL, Terrault NA. National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature. Hepatology. 2024;79(3):666\u201373.","journal-title":"Hepatology"},{"issue":"6","key":"712_CR19","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/j.1478-3231.2012.02781.x","volume":"32","author":"RP Myers","year":"2012","unstructured":"Myers RP, et al. Controlled attenuation parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int. 2012;32(6):902\u201310.","journal-title":"Liver Int"},{"issue":"6","key":"712_CR20","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nrgastro.2017.32","volume":"14","author":"NL Gluchowski","year":"2017","unstructured":"Gluchowski NL, et al. Lipid droplets and liver disease: from basic biology to clinical implications. Nat Rev Gastroenterol Hepatol. 2017;14(6):343\u201355.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"712_CR21","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev-pathol-020117-043617","volume":"13","author":"JP Arab","year":"2018","unstructured":"Arab JP, Arrese M, Trauner M. Recent insights into the pathogenesis of nonalcoholic fatty liver disease. Annu Rev Pathol. 2018;13(1):321\u201350.","journal-title":"Annu Rev Pathol"},{"issue":"5","key":"712_CR22","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1002\/hep.32675","volume":"77","author":"M Mathur","year":"2023","unstructured":"Mathur M, et al. Adipose lipolysis is important for ethanol to induce fatty liver in the National Institute on Alcohol Abuse and Alcoholism murine model of chronic and binge ethanol feeding. Hepatology. 2023;77(5):1688\u2013701.","journal-title":"Hepatology"},{"issue":"18","key":"712_CR23","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1007\/s00018-018-2860-6","volume":"75","author":"DH Ipsen","year":"2018","unstructured":"Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci. 2018;75(18):3313\u201327.","journal-title":"Cell Mol Life Sci"},{"key":"712_CR24","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1146\/annurev-pathmechdis-031521-030435","volume":"18","author":"X Wu","year":"2023","unstructured":"Wu X, et al. Recent advances in understanding of pathogenesis of alcohol-associated liver disease. Annu Rev Pathol. 2023;18:411\u201338.","journal-title":"Annu Rev Pathol"},{"key":"712_CR25","doi-asserted-by":"publisher","first-page":"112789","DOI":"10.1016\/j.biopha.2022.112789","volume":"148","author":"ME Shaker","year":"2022","unstructured":"Shaker ME. The contribution of sterile inflammation to the fatty liver disease and the potential therapies. Biomed Pharmacother. 2022;148:112789.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"712_CR26","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.cell.2021.12.018","volume":"185","author":"M Guilliams","year":"2022","unstructured":"Guilliams M, et al. Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches. Cell. 2022;185(2):379-396 e38.","journal-title":"Cell"},{"issue":"2","key":"712_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108626","volume":"34","author":"S Daemen","year":"2021","unstructured":"Daemen S, et al. Dynamic shifts in the composition of resident and recruited macrophages influence tissue remodeling in NASH. Cell Rep. 2021;34(2):108626.","journal-title":"Cell Rep"},{"issue":"5","key":"712_CR28","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.jhep.2015.12.005","volume":"64","author":"A Boussif","year":"2016","unstructured":"Boussif A, et al. Impaired intracellular signaling, myeloperoxidase release and bactericidal activity of neutrophils from patients with alcoholic cirrhosis. J Hepatol. 2016;64(5):1041\u20138.","journal-title":"J Hepatol"},{"key":"712_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.751802","volume":"12","author":"S Hwang","year":"2021","unstructured":"Hwang S, et al. Role of neutrophils in the pathogenesis of nonalcoholic steatohepatitis. Front Endocrinol (Lausanne). 2021;12:751802.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"712_CR30","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/s41591-021-01344-3","volume":"27","author":"A Deczkowska","year":"2021","unstructured":"Deczkowska A, et al. XCR1(+) type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis. Nat Med. 2021;27(6):1043\u201354.","journal-title":"Nat Med"},{"issue":"2","key":"712_CR31","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.jhep.2020.04.001","volume":"73","author":"J Gautheron","year":"2020","unstructured":"Gautheron J, Gores GJ, Rodrigues CMP. Lytic cell death in metabolic liver disease. J Hepatol. 2020;73(2):394\u2013408.","journal-title":"J Hepatol"},{"issue":"4","key":"712_CR32","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.jhep.2022.06.012","volume":"77","author":"M Peiseler","year":"2022","unstructured":"Peiseler M, et al. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits. J Hepatol. 2022;77(4):1136\u201360.","journal-title":"J Hepatol"},{"issue":"1","key":"712_CR33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jcmgh.2014.11.005","volume":"1","author":"P Hirsova","year":"2015","unstructured":"Hirsova P, Gores GJ. Death receptor-mediated cell death and proinflammatory signaling in nonalcoholic steatohepatitis. Cell Mol Gastroenterol Hepatol. 2015;1(1):17\u201327.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"8","key":"712_CR34","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1111\/jgh.16199","volume":"38","author":"MH Jew","year":"2023","unstructured":"Jew MH, Hsu CL. Alcohol, the gut microbiome, and liver disease. J Gastroenterol Hepatol. 2023;38(8):1205\u201310.","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"712_CR35","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/MOG.0000000000000927","volume":"39","author":"V Ajmera","year":"2023","unstructured":"Ajmera V, Loomba R. Advances in the genetics of nonalcoholic fatty liver disease. Curr Opin Gastroenterol. 2023;39(3):150\u20135.","journal-title":"Curr Opin Gastroenterol"},{"issue":"10","key":"712_CR36","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.34221","volume":"5","author":"HS Kim","year":"2022","unstructured":"Kim HS, et al. Synergistic associations of PNPLA3 I148M variant, alcohol intake, and obesity with risk of cirrhosis, hepatocellular carcinoma, and mortality. JAMA Netw Open. 2022;5(10):e2234221.","journal-title":"JAMA Netw Open"},{"issue":"10","key":"712_CR37","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1038\/s41591-023-02553-8","volume":"29","author":"A Cherubini","year":"2023","unstructured":"Cherubini A, et al. Interaction between estrogen receptor-alpha and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women. Nat Med. 2023;29(10):2643\u201355.","journal-title":"Nat Med"},{"issue":"6","key":"712_CR38","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/j.jhep.2020.02.020","volume":"72","author":"E Trepo","year":"2020","unstructured":"Trepo E, Valenti L. Update on NAFLD genetics: from new variants to the clinic. J Hepatol. 2020;72(6):1196\u2013209.","journal-title":"J Hepatol"},{"issue":"3","key":"712_CR39","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/hep.31238","volume":"72","author":"H Gellert-Kristensen","year":"2020","unstructured":"Gellert-Kristensen H, et al. Combined effect of PNPLA3, TM6SF2, and HSD17B13 variants on risk of cirrhosis and hepatocellular carcinoma in the general population. Hepatology. 2020;72(3):845\u201356.","journal-title":"Hepatology"},{"issue":"7","key":"712_CR40","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s12272-022-01392-4","volume":"45","author":"SH Park","year":"2022","unstructured":"Park SH, et al. Alcoholic liver disease: a new insight into the pathogenesis of liver disease. Arch Pharm Res. 2022;45(7):447\u201359.","journal-title":"Arch Pharm Res"},{"issue":"1","key":"712_CR41","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/hep.23258","volume":"51","author":"RS O'Shea","year":"2010","unstructured":"O\u2019Shea RS, et al. Alcoholic liver disease. Hepatology. 2010;51(1):307\u201328.","journal-title":"Hepatology"},{"issue":"1","key":"712_CR42","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jhep.2022.08.030","volume":"78","author":"F Aberg","year":"2023","unstructured":"Aberg F, et al. Alcohol consumption and metabolic syndrome: clinical and epidemiological impact on liver disease. J Hepatol. 2023;78(1):191\u2013206.","journal-title":"J Hepatol"},{"issue":"2","key":"712_CR43","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jhep.2017.11.006","volume":"68","author":"M Boyle","year":"2018","unstructured":"Boyle M, Masson S, Anstee QM. The bidirectional impacts of alcohol consumption and the metabolic syndrome: cofactors for progressive fatty liver disease. J Hepatol. 2018;68(2):251\u201367.","journal-title":"J Hepatol"},{"issue":"9","key":"712_CR44","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1111\/liv.13408","volume":"37","author":"F Aberg","year":"2017","unstructured":"Aberg F, et al. Binge drinking and the risk of liver events: a population-based cohort study. Liver Int. 2017;37(9):1373\u201381.","journal-title":"Liver Int"},{"issue":"8","key":"712_CR45","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.cgh.2020.11.038","volume":"20","author":"M Israelsen","year":"2022","unstructured":"Israelsen M, et al. Metabolic and genetic risk factors are the strongest predictors of severity of alcohol-related liver fibrosis. Clin Gastroenterol Hepatol. 2022;20(8):1784-1794 e9.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"712_CR46","doi-asserted-by":"publisher","first-page":"106","DOI":"10.14309\/ajg.0000000000000833","volume":"116","author":"JB Whitfield","year":"2021","unstructured":"Whitfield JB, et al. Obesity, diabetes, coffee, tea, and cannabis use alter risk for alcohol-related cirrhosis in 2 large cohorts of high-risk drinkers. Am J Gastroenterol. 2021;116(1):106\u201315.","journal-title":"Am J Gastroenterol"},{"key":"712_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154439","volume":"115","author":"J Blomdahl","year":"2021","unstructured":"Blomdahl J, et al. Moderate alcohol consumption is associated with advanced fibrosis in non-alcoholic fatty liver disease and shows a synergistic effect with type 2 diabetes mellitus. Metabolism. 2021;115:154439.","journal-title":"Metabolism"},{"issue":"2","key":"712_CR48","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/hep.32123","volume":"75","author":"H Innes","year":"2022","unstructured":"Innes H, et al. Characterizing the risk interplay between alcohol intake and body mass index on cirrhosis morbidity. Hepatology. 2022;75(2):369\u201378.","journal-title":"Hepatology"},{"key":"712_CR49","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c1240","volume":"340","author":"CL Hart","year":"2010","unstructured":"Hart CL, et al. Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies. BMJ. 2010;340:c1240.","journal-title":"BMJ"},{"issue":"1","key":"712_CR50","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.alcohol.2004.07.010","volume":"34","author":"AM Diehl","year":"2004","unstructured":"Diehl AM. Obesity and alcoholic liver disease. Alcohol. 2004;34(1):81\u20137.","journal-title":"Alcohol"},{"issue":"11\u201312","key":"712_CR51","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1111\/j.1365-2036.2009.04141.x","volume":"30","author":"R Loomba","year":"2009","unstructured":"Loomba R, Bettencourt R, Barrett-Connor E. Synergistic association between alcohol intake and body mass index with serum alanine and aspartate aminotransferase levels in older adults: the Rancho Bernardo study. Aliment Pharmacol Ther. 2009;30(11\u201312):1137\u201349.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"712_CR52","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.jhep.2024.06.036","volume":"81","author":"D Marti-Aguado","year":"2024","unstructured":"Marti-Aguado D, et al. Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease. J Hepatol. 2024;81(6):930\u201340.","journal-title":"J Hepatol"},{"issue":"4","key":"712_CR53","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1093\/aje\/kws252","volume":"177","author":"R Loomba","year":"2013","unstructured":"Loomba R, et al. Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study. Am J Epidemiol. 2013;177(4):333\u201342.","journal-title":"Am J Epidemiol"},{"issue":"5","key":"712_CR54","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.cgh.2022.08.019","volume":"21","author":"M Noureddin","year":"2023","unstructured":"Noureddin M, Wong VW. A revisit of the natural history of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2023;21(5):1152\u20133.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"712_CR55","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/HEP.0000000000000925","volume":"81","author":"M Kwak","year":"2025","unstructured":"Kwak M, et al. MASLD\/MetALD and mortality in individuals with any cardio-metabolic risk factor: a population-based study with 26.7 years of follow-up. Hepatology. 2025;81(1):228\u201337.","journal-title":"Hepatology"},{"issue":"2","key":"712_CR56","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1016\/j.jhep.2023.09.014","volume":"80","author":"D Kim","year":"2024","unstructured":"Kim D, et al. Metabolic dysfunction-associated steatotic liver disease and all-cause\/cause-specific mortality among adults in the United States. J Hepatol. 2024;80(2):e79\u201381.","journal-title":"J Hepatol"},{"issue":"1","key":"712_CR57","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/apt.18015","volume":"60","author":"N Tamaki","year":"2024","unstructured":"Tamaki N, et al. Long-term clinical outcomes in steatotic liver disease and incidence of liver-related events, cardiovascular events and all-cause mortality. Aliment Pharmacol Ther. 2024;60(1):61\u20139.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"712_CR58","doi-asserted-by":"publisher","first-page":"410","DOI":"10.14309\/ajg.0000000000002920","volume":"120","author":"B Yun","year":"2025","unstructured":"Yun B, et al. Liver cancer risk across metabolic dysfunction-associated steatotic liver disease and\/or alcohol: a nationwide study. Am J Gastroenterol. 2025;120(2):410\u20139.","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"712_CR59","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.14309\/ajg.0000000000002778","volume":"119","author":"YT Chen","year":"2024","unstructured":"Chen YT, et al. Long-term risks of cirrhosis and hepatocellular carcinoma across steatotic liver disease subtypes. Am J Gastroenterol. 2024;119(11):2241\u201350.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"712_CR60","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1097\/HEP.0000000000000664","volume":"79","author":"CM Lee","year":"2024","unstructured":"Lee CM, et al. Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings. Hepatology. 2024;79(6):1393\u2013400.","journal-title":"Hepatology"},{"key":"712_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.155800","volume":"153","author":"HJ Choe","year":"2024","unstructured":"Choe HJ, et al. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: a community-dwelling cohort study with 20-year follow-up. Metabolism. 2024;153:155800.","journal-title":"Metabolism"},{"issue":"1","key":"712_CR62","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/hep.30170","volume":"69","author":"Y Chang","year":"2019","unstructured":"Chang Y, et al. Nonheavy drinking and worsening of noninvasive fibrosis markers in nonalcoholic fatty liver disease: a cohort study. Hepatology. 2019;69(1):64\u201375.","journal-title":"Hepatology"},{"issue":"9","key":"712_CR63","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/j.cgh.2018.01.026","volume":"16","author":"V Ajmera","year":"2018","unstructured":"Ajmera V, et al. Among patients with nonalcoholic fatty liver disease, modest alcohol use is associated with less improvement in histologic steatosis and steatohepatitis. Clin Gastroenterol Hepatol. 2018;16(9):1511-1520 e5.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"712_CR64","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/liv.12230","volume":"34","author":"HK Kwon","year":"2014","unstructured":"Kwon HK, Greenson JK, Conjeevaram HS. Effect of lifetime alcohol consumption on the histological severity of non-alcoholic fatty liver disease. Liver Int. 2014;34(1):129\u201335.","journal-title":"Liver Int"},{"issue":"8","key":"712_CR65","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/apt.17388","volume":"57","author":"L Magherman","year":"2023","unstructured":"Magherman L, et al. Meta-analysis: the impact of light-to-moderate alcohol consumption on progressive non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2023;57(8):820\u201336.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"712_CR66","doi-asserted-by":"publisher","first-page":"e64","DOI":"10.1016\/j.jhep.2023.08.021","volume":"80","author":"L Chen","year":"2024","unstructured":"Chen L, et al. Clinical and histological features under different nomenclatures of fatty liver disease: NAFLD, MAFLD, MASLD and MetALD. J Hepatol. 2024;80(2):e64\u20136.","journal-title":"J Hepatol"},{"issue":"2","key":"712_CR67","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1016\/j.jhep.2023.07.007","volume":"80","author":"KM Schneider","year":"2024","unstructured":"Schneider KM, Schneider CV. A new era for steatotic liver disease: evaluating the novel nomenclature in the UK Biobank. J Hepatol. 2024;80(2):e58\u201360.","journal-title":"J Hepatol"},{"issue":"4","key":"712_CR68","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1053\/j.gastro.2023.06.013","volume":"165","author":"JJ Wattacheril","year":"2023","unstructured":"Wattacheril JJ, et al. AGA clinical practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: expert review. Gastroenterology. 2023;165(4):1080\u20138.","journal-title":"Gastroenterology"},{"issue":"3","key":"712_CR69","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1053\/gast.2002.35354","volume":"123","author":"S Saadeh","year":"2002","unstructured":"Saadeh S, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123(3):745\u201350.","journal-title":"Gastroenterology"},{"issue":"4","key":"712_CR70","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1002\/hep.29639","volume":"67","author":"C Caussy","year":"2018","unstructured":"Caussy C, et al. Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis. Hepatology. 2018;67(4):1348\u201359.","journal-title":"Hepatology"},{"issue":"1","key":"712_CR71","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/j.1365-2036.2012.05121.x","volume":"36","author":"Z Permutt","year":"2012","unstructured":"Permutt Z, et al. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther. 2012;36(1):22\u20139.","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"712_CR72","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.ultrasmedbio.2010.07.005","volume":"36","author":"M Sasso","year":"2010","unstructured":"Sasso M, et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36(11):1825\u201335.","journal-title":"Ultrasound Med Biol"},{"issue":"4","key":"712_CR73","doi-asserted-by":"publisher","first-page":"736","DOI":"10.3390\/medicina61040736","volume":"61","author":"J Fraczek","year":"2025","unstructured":"Fraczek J, et al. Non-Invasive Tests as a Replacement for Liver Biopsy in the Assessment of MASLD. Medicina. 2025;61(4):736.","journal-title":"Medicina"},{"issue":"2","key":"712_CR74","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/ueg2.12525","volume":"12","author":"J Zeng","year":"2024","unstructured":"Zeng J, Fan JG, Francque SM. Therapeutic management of metabolic dysfunction associated steatotic liver disease. United Eur Gastroenterol J. 2024;12(2):177\u201386.","journal-title":"United Eur Gastroenterol J"},{"issue":"4","key":"712_CR75","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1097\/MEG.0000000000002715","volume":"36","author":"MT Abuelazm","year":"2024","unstructured":"Abuelazm MT, et al. Intermittent fasting regimens for metabolic dysfunction-associated steatotic liver disease: a systematic review and network meta-analysis of randomized controlled trials. Eur J Gastroenterol Hepatol. 2024;36(4):371\u201381.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"712_CR76","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ajcnut.2024.10.012","volume":"121","author":"X Sun","year":"2025","unstructured":"Sun X, et al. Intermittent compared with continuous calorie restriction for treatment of metabolic dysfunction-associated steatotic liver disease: a randomized clinical trial. Am J Clin Nutr. 2025;121(1):158\u201366.","journal-title":"Am J Clin Nutr"},{"key":"712_CR77","doi-asserted-by":"publisher","DOI":"10.3390\/nu17030472","author":"S Garcia","year":"2025","unstructured":"Garcia S, et al. Ultra-processed food consumption and metabolic-dysfunction-associated steatotic liver disease (MASLD): a longitudinal and sustainable analysis. Nutrients. 2025. https:\/\/doi.org\/10.3390\/nu17030472.","journal-title":"Nutrients"},{"key":"712_CR78","doi-asserted-by":"publisher","DOI":"10.3390\/foods14101736","author":"M Monserrat-Mesquida","year":"2025","unstructured":"Monserrat-Mesquida M, et al. Two-year Mediterranean diet intervention improves hepatic health in MASLD patients. Foods. 2025. https:\/\/doi.org\/10.3390\/foods14101736.","journal-title":"Foods"},{"key":"712_CR79","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2024.1426551","volume":"11","author":"SP Mambrini","year":"2024","unstructured":"Mambrini SP, et al. Diet and physical exercise as key players to tackle MASLD through improvement of insulin resistance and metabolic flexibility. Front Nutr. 2024;11:1426551.","journal-title":"Front Nutr"},{"issue":"19","key":"712_CR80","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1001\/jama.2018.14854","volume":"320","author":"KL Piercy","year":"2018","unstructured":"Piercy KL, et al. The physical activity guidelines for Americans. JAMA. 2018;320(19):2020\u20138.","journal-title":"JAMA"},{"issue":"3","key":"712_CR81","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1053\/j.gastro.2020.11.051","volume":"160","author":"ZM Younossi","year":"2021","unstructured":"Younossi ZM, Corey KE, Lim JK. AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review. Gastroenterology. 2021;160(3):912\u20138.","journal-title":"Gastroenterology"},{"issue":"3","key":"712_CR82","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1053\/j.gastro.2022.06.023","volume":"163","author":"MT Long","year":"2022","unstructured":"Long MT, Noureddin M, Lim JK. AGA clinical practice update: diagnosis and management of nonalcoholic fatty liver disease in lean individuals: expert review. Gastroenterology. 2022;163(3):764-774 e1.","journal-title":"Gastroenterology"},{"issue":"9","key":"712_CR83","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aax4043","volume":"5","author":"K Witkiewitz","year":"2019","unstructured":"Witkiewitz K, Litten RZ, Leggio L. Advances in the science and treatment of alcohol use disorder. Sci Adv. 2019;5(9):eaax4043.","journal-title":"Sci Adv"},{"issue":"1","key":"712_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2023.101162","volume":"29","author":"H Hernandez-Evole","year":"2024","unstructured":"Hernandez-Evole H, et al. Alcohol-associated liver disease: epidemiology and management. Ann Hepatol. 2024;29(1):101162.","journal-title":"Ann Hepatol"},{"key":"712_CR85","doi-asserted-by":"crossref","unstructured":"Petry NM, L.D., McKay JR, Treatment of substance use disorders, ed. C.D. Kranzler HR, Zindel LR. 2013: American Psychiatric Publication.","DOI":"10.1176\/appi.books.9781585625284.lg10"},{"issue":"6","key":"712_CR86","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1097\/HEP.0000000000000935","volume":"80","author":"GW Marek","year":"2024","unstructured":"Marek GW, Malhi H. MetALD: does it require a different therapeutic option? Hepatology. 2024;80(6):1424\u201340.","journal-title":"Hepatology"},{"issue":"8","key":"712_CR87","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1001\/jama.2018.11406","volume":"320","author":"HR Kranzler","year":"2018","unstructured":"Kranzler HR, Soyka M. Diagnosis and pharmacotherapy of alcohol use disorder: a review. JAMA. 2018;320(8):815\u201324.","journal-title":"JAMA"},{"issue":"1","key":"712_CR88","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jhep.2018.03.018","volume":"69","author":"European Association for the Study of the, L.","year":"2018","unstructured":"European Association for the Study of the, L. EASL clinical practice guidelines: management of alcohol-related liver disease. J Hepatol. 2018;69(1):154\u201381.","journal-title":"J Hepatol"},{"issue":"6","key":"712_CR89","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390(6):497\u2013509.","journal-title":"N Engl J Med"},{"issue":"23","key":"712_CR90","doi-asserted-by":"publisher","first-page":"13105","DOI":"10.3390\/ijms222313105","volume":"22","author":"A Caddeo","year":"2021","unstructured":"Caddeo A, et al. TG68, a Novel Thyroid Hormone Receptor-beta Agonist for the Treatment of NAFLD. Int J Mol Sci. 2021;22(23):13105.","journal-title":"Int J Mol Sci"},{"issue":"10213","key":"712_CR91","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","volume":"394","author":"SA Harrison","year":"2019","unstructured":"Harrison SA, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019;394(10213):2012\u201324.","journal-title":"Lancet"},{"issue":"18","key":"712_CR92","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","volume":"362","author":"AJ Sanyal","year":"2010","unstructured":"Sanyal AJ, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675\u201385.","journal-title":"N Engl J Med"},{"issue":"2","key":"712_CR93","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1002\/hep.30368","volume":"71","author":"E Vilar-Gomez","year":"2020","unstructured":"Vilar-Gomez E, et al. Vitamin E improves transplant-free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis. Hepatology. 2020;71(2):495\u2013509.","journal-title":"Hepatology"},{"issue":"5","key":"712_CR94","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1053\/j.gastro.2004.02.015","volume":"126","author":"N Chalasani","year":"2004","unstructured":"Chalasani N, et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004;126(5):1287\u201392.","journal-title":"Gastroenterology"},{"issue":"5","key":"712_CR95","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1002\/hep.21848","volume":"46","author":"JH Lewis","year":"2007","unstructured":"Lewis JH, et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology. 2007;46(5):1453\u201363.","journal-title":"Hepatology"},{"issue":"6","key":"712_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2022.100738","volume":"27","author":"M Abdallah","year":"2022","unstructured":"Abdallah M, et al. Safety and efficacy of dyslipidemia treatment in NAFLD patients: a meta-analysis of randomized controlled trials. Ann Hepatol. 2022;27(6):100738.","journal-title":"Ann Hepatol"},{"issue":"11","key":"712_CR97","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1136\/gutjnl-2024-333074","volume":"73","author":"XD Zhou","year":"2024","unstructured":"Zhou XD, et al. Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease. Gut. 2024;73(11):1883\u201392.","journal-title":"Gut"},{"issue":"4","key":"712_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101313","volume":"7","author":"B Yun","year":"2025","unstructured":"Yun B, et al. Statin use and liver-related prognosis among patients with MASLD. JHEP Rep. 2025;7(4):101313.","journal-title":"JHEP Rep"},{"issue":"5","key":"712_CR99","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.jhep.2021.12.034","volume":"76","author":"N Mahmud","year":"2022","unstructured":"Mahmud N, et al. Statin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort. J Hepatol. 2022;76(5):1100\u20138.","journal-title":"J Hepatol"},{"issue":"6","key":"712_CR100","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1007\/s10620-015-4000-6","volume":"61","author":"P Blais","year":"2016","unstructured":"Blais P, et al. Statins are underutilized in patients with nonalcoholic fatty liver disease and dyslipidemia. Dig Dis Sci. 2016;61(6):1714\u201320.","journal-title":"Dig Dis Sci"},{"issue":"5","key":"712_CR101","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1210\/jc.2015-3291","volume":"101","author":"JS Ten Kulve","year":"2016","unstructured":"Ten Kulve JS, et al. Decreased hypothalamic glucagon-like peptide-1 receptor expression in type 2 diabetes patients. J Clin Endocrinol Metab. 2016;101(5):2122\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"712_CR102","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113\u201324.","journal-title":"N Engl J Med"},{"issue":"6","key":"712_CR103","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","volume":"10","author":"A Gastaldelli","year":"2022","unstructured":"Gastaldelli A, et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022;10(6):393\u2013406.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"712_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104642","volume":"93","author":"C Aranas","year":"2023","unstructured":"Aranas C, et al. Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats. EBioMedicine. 2023;93:104642.","journal-title":"EBioMedicine"},{"issue":"1","key":"712_CR105","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48780-6","volume":"15","author":"W Wang","year":"2024","unstructured":"Wang W, et al. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nat Commun. 2024;15(1):4548.","journal-title":"Nat Commun"},{"issue":"4","key":"712_CR106","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","volume":"82","author":"CS Hendershot","year":"2025","unstructured":"Hendershot CS, et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatr. 2025;82(4):395\u2013405.","journal-title":"JAMA Psychiatr"},{"issue":"12","key":"712_CR107","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","volume":"8","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, et al. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterol Hepatol. 2023;8(12):1080\u201393.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"712_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100563","volume":"5","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, et al. A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis. JHEP Rep. 2023;5(1):100563.","journal-title":"JHEP Rep"},{"issue":"2","key":"712_CR109","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.cmet.2021.12.024","volume":"34","author":"KH Flippo","year":"2022","unstructured":"Flippo KH, et al. FGF21 suppresses alcohol consumption through an amygdalo-striatal circuit. Cell Metab. 2022;34(2):317\u201328.","journal-title":"Cell Metab"},{"issue":"11","key":"712_CR110","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.molmet.2017.08.004","volume":"6","author":"BN Desai","year":"2017","unstructured":"Desai BN, et al. Fibroblast growth factor 21 (FGF21) is robustly induced by ethanol and has a protective role in ethanol associated liver injury. Mol Metab. 2017;6(11):1395\u2013406.","journal-title":"Mol Metab"},{"issue":"2","key":"712_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101250","volume":"7","author":"J Gratacos-Gines","year":"2025","unstructured":"Gratacos-Gines J, et al. MetALD: clinical aspects, pathophysiology and treatment. JHEP Rep. 2025;7(2):101250.","journal-title":"JHEP Rep"},{"issue":"10215","key":"712_CR112","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","volume":"394","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394(10215):2184\u201396.","journal-title":"Lancet"},{"issue":"17","key":"712_CR113","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","volume":"385","author":"SM Francque","year":"2021","unstructured":"Francque SM, et al. A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH. N Engl J Med. 2021;385(17):1547\u201358.","journal-title":"N Engl J Med"},{"issue":"1","key":"712_CR114","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jhep.2021.01.047","volume":"75","author":"SA Harrison","year":"2021","unstructured":"Harrison SA, et al. A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis. J Hepatol. 2021;75(1):25\u201333.","journal-title":"J Hepatol"},{"issue":"3","key":"712_CR115","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jhep.2022.10.023","volume":"78","author":"V Ratziu","year":"2023","unstructured":"Ratziu V, et al. Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH. J Hepatol. 2023;78(3):479\u201392.","journal-title":"J Hepatol"},{"key":"712_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2021.153629","volume":"90","author":"L Kong","year":"2021","unstructured":"Kong L, et al. Yangonin modulates lipid homeostasis, ameliorates cholestasis and cellular senescence in alcoholic liver disease via activating nuclear receptor FXR. Phytomedicine. 2021;90:153629.","journal-title":"Phytomedicine"},{"issue":"1","key":"712_CR117","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.bbrc.2013.11.057","volume":"443","author":"W Wu","year":"2014","unstructured":"Wu W, et al. Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease. Biochem Biophys Res Commun. 2014;443(1):68\u201373.","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"712_CR118","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"K Cusi","year":"2022","unstructured":"Cusi K, et al. American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022;28(5):528\u201362.","journal-title":"Endocr Pract"},{"issue":"4","key":"712_CR119","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","volume":"159","author":"G Lassailly","year":"2020","unstructured":"Lassailly G, et al. Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis. Gastroenterology. 2020;159(4):1290\u2013301.","journal-title":"Gastroenterology"},{"issue":"23","key":"712_CR120","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1001\/jama.2012.6147","volume":"307","author":"WC King","year":"2012","unstructured":"King WC, et al. Prevalence of alcohol use disorders before and after bariatric surgery. JAMA. 2012;307(23):2516\u201325.","journal-title":"JAMA"},{"issue":"12","key":"712_CR121","doi-asserted-by":"publisher","first-page":"e956","DOI":"10.1016\/S2468-2667(23)00217-7","volume":"8","author":"IY Millwood","year":"2023","unstructured":"Millwood IY, et al. Alcohol intake and cause-specific mortality: conventional and genetic evidence in a prospective cohort study of 512 000 adults in China. Lancet Public Health. 2023;8(12):e956\u201367.","journal-title":"Lancet Public Health"},{"issue":"6","key":"712_CR122","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1053\/j.gastro.2024.02.032","volume":"166","author":"RJ Wong","year":"2024","unstructured":"Wong RJ, et al. Impact of longitudinal alcohol use patterns on long-term risk of cirrhosis among US veterans with steatotic liver disease. Gastroenterology. 2024;166(6):1156-1165 e4.","journal-title":"Gastroenterology"},{"issue":"1","key":"712_CR123","doi-asserted-by":"publisher","first-page":"30","DOI":"10.14309\/ajg.0000000000002572","volume":"119","author":"LL Jophlin","year":"2024","unstructured":"Jophlin LL, et al. ACG clinical guideline: alcohol-associated liver disease. Am J Gastroenterol. 2024;119(1):30\u201354.","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"712_CR124","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1038\/s41591-024-03223-z","volume":"30","author":"F Zannad","year":"2024","unstructured":"Zannad F, et al. Integrating liver endpoints in clinical trials of cardiovascular and kidney disease. Nat Med. 2024;30(9):2423\u201331.","journal-title":"Nat Med"},{"key":"712_CR125","unstructured":"Food and Drug Administration, C.f.D.E.a.R.C. Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment Guidance for Industry Draft Guidance [Internet],. 2018 7\/15\/25]; Available from: Available from: https:\/\/www.fda.gov\/media\/119044\/download."},{"key":"712_CR126","unstructured":"FDA. Nonalcoholic Steatohepatitis with Compensated Cirrhosis: Developing Drugs for Treatment Guidance for Industry [Internet]. 2019 7\/15\/25]; Available from: https:\/\/www.fda.gov\/media\/127738\/download."},{"issue":"10","key":"712_CR127","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1016\/j.cgh.2019.04.018","volume":"17","author":"M Balakrishnan","year":"2019","unstructured":"Balakrishnan M, Loomba R. PROs of patient-reported outcomes for nonalcoholic fatty liver disease and effects on treatment for nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2019;17(10):1950\u20133.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"712_CR128","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.cgh.2024.01.006","volume":"22","author":"P Nasr","year":"2024","unstructured":"Nasr P, et al. Misclassified alcohol-related liver disease is common in presumed metabolic dysfunction-associated steatotic liver disease and highly increases risk for future cirrhosis. Clin Gastroenterol Hepatol. 2024;22(5):1048-1057 e2.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"712_CR129","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.05.030","author":"F Tavaglione","year":"2025","unstructured":"Tavaglione F, et al. Clinical utility of phosphatidylethanol to detect underreported alcohol use and enhance steatotic liver disease subclassification. J Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.jhep.2025.05.030.","journal-title":"J Hepatol"},{"issue":"8","key":"712_CR130","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0255801","volume":"16","author":"J Lankester","year":"2021","unstructured":"Lankester J, et al. Alcohol use and cardiometabolic risk in the UK Biobank: a Mendelian randomization study. PLoS One. 2021;16(8):e0255801.","journal-title":"PLoS One"},{"key":"712_CR131","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.clnesp.2023.09.927","volume":"58","author":"F Pashayee-Khamene","year":"2023","unstructured":"Pashayee-Khamene F, et al. Keeping an eye on the nutrition: the importance of nutrition management on cardiometabolic risk factors in cirrhotic patients. Clin Nutr ESPEN. 2023;58:186\u201392.","journal-title":"Clin Nutr ESPEN"}],"container-title":["Current Hepatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11901-025-00712-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11901-025-00712-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11901-025-00712-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T07:03:08Z","timestamp":1769410988000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11901-025-00712-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":131,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["712"],"URL":"https:\/\/doi.org\/10.1007\/s11901-025-00712-8","relation":{},"ISSN":["2195-9595"],"issn-type":[{"value":"2195-9595","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"30 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article did not require approval of Ethics committee or Internal Review Boards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"This article does not contain any studies with human or animal studies performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}